Managing patients with metastatic breast cancer and experience of eribulin
Art & Science Previous     Next

Managing patients with metastatic breast cancer and experience of eribulin

Elaine Lennan Nurse consultant, University Hospital Southampton NHS Foundation Trust
Helen Roe Consultant cancer nurse, North Cumbria University Hospitals NHS Trust
Jason Chow Specialist registrar medical oncology, Guy’s and St Thomas’ NHS Foundation Trust, London
Mark Harries Consultant medical oncologist, Guy’s and St Thomas’ NHS Foundation Trust, London

Elaine Lennan and colleagues explain how personalised therapy and chemotherapeutic sequencing regimens can improve care

Management of patients with metastatic breast cancer (MBC) is changing with the development of promising novel therapies such as eribulin. Effective patient management can be facilitated through a multidisciplinary team approach, taking into consideration multiple factors including guidelines and, from a UK perspective, national policies dictated by government. This article provides an overview of current practice in the management of patients with MBC and how it can be improved through wider considerations including treatment goals, personalised therapy and chemotherapeutic sequencing regimens. Specialist nurse support is an important part of caring for patients with MBC. In addition to helping patients to consider treatment options and managing palliative care in late disease, nurses offer vital psychological support to patients and their families or carers. The lack of metastatic breast cancer nurses requires urgent attention if the aims of national policy are to be met.

Cancer Nursing Practice. 14, 10,29-36. doi: 10.7748/cnp.14.10.29.s22

Correspondence

helen.roe@ncuh.nhs.uk

Peer review

This article has been subject to double-blind review and checked using antiplagiarism software

Conflict of interest

Succinct Medical Communications provided medical writing and editorial assistance in the preparation of this manuscript. The authors were financially supported by Eisai Ltd, Hatfield, UK, but retained full control over the content with no input from Eisai except for a factual accuracy check. The decision to publish is entirely the authors’. Elaine Lennan reports personal fees from paid lecture and personal fees from chairmanship, outside the submitted work. Helen Roe reports personal fees from an education session at the UK Oncology Nursing Society conference 2014, outside the submitted work. Jason Chow has no conflict of interest to disclose. Mark Harries reports honoraria for speaking for Eisai Co Ltd, outside the submitted work.

Received: 20 April 2015

Accepted: 05 November 2015